BioPharma Credit Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Other Revenue	154.66	150.03	135.74	218.17	103.88	110.02
Revenue	154.66	150.03	135.74	218.17	103.88	110.02
Revenue Growth (YoY)	13.42%	10.53%	-37.78%	110.02%	-5.58%	-27.09%
Gross Profit	154.66	150.03	135.74	218.17	103.88	110.02
Selling, General & Admin	31.65	27.72	27.28	35.79	18.95	20.87
Other Operating Expenses	-0.08	0.13	0	0.04	-0.05	-
Operating Expenses	31.56	27.85	27.28	35.83	18.9	20.87
Operating Income	123.1	122.18	108.46	182.34	84.98	89.15
Currency Exchange Gain (Loss)	0.02	-0	-0.01	-0.03	-0.02	-0.01
Pretax Income	123.12	122.18	108.45	182.31	84.96	89.14
Net Income	123.12	122.18	108.45	182.31	84.96	89.14
Net Income to Common	123.12	122.18	108.45	182.31	84.96	89.14
Net Income Growth	12.58%	12.66%	-40.51%	114.59%	-4.69%	-27.13%
Shares Outstanding (Basic)	1,174	1,222	1,309	1,364	1,374	1,374
Shares Outstanding (Diluted)	1,174	1,222	1,309	1,364	1,374	1,374
Shares Change (YoY)	-7.85%	-6.65%	-4.00%	-0.72%	-0.00%	-0.00%
EPS (Basic)	0.10	0.10	0.08	0.13	0.06	0.06
EPS (Diluted)	0.10	0.10	0.08	0.13	0.06	0.06
EPS Growth	22.17%	20.68%	-38.03%	116.14%	-4.68%	-27.13%
Dividend Per Share	0.070	0.070	0.070	0.070	0.070	0.070
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	79.59%	81.44%	79.90%	83.58%	81.80%	81.03%
Profit Margin	79.61%	81.44%	79.90%	83.56%	81.79%	81.02%
EBIT	123.1	122.18	108.46	182.34	84.98	89.15
EBIT Margin	79.59%	81.44%	79.90%	83.58%	81.80%	81.03%
Revenue as Reported	154.69	150.03	135.73	218.14	103.86	110.01

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.